Capital Research Global Investors Gilead Sciences, Inc. Transaction History
Capital Research Global Investors
- $479 Billion
- Q2 2025
A detailed history of Capital Research Global Investors transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Capital Research Global Investors holds 31,097,679 shares of GILD stock, worth $3.73 Billion. This represents 0.72% of its overall portfolio holdings.
Number of Shares
31,097,679
Previous 54,610,370
43.06%
Holding current value
$3.73 Billion
Previous $6.12 Billion
43.66%
% of portfolio
0.72%
Previous 1.39%
Shares
32 transactions
Others Institutions Holding GILD
# of Institutions
2,321Shares Held
1.02BCall Options Held
12MPut Options Held
9.14M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$7.1 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.56 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.5 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $150B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...